Your daily source for AI news, tools reviews, and practical guides to artificial intelligence
Converge Bio, an AI-focused drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with notable support from executives at Meta, OpenAI, and Wiz.
Converge Bio, a startup specializing in artificial intelligence for drug discovery, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with notable support from executives at Meta, OpenAI, and Wiz.
A significant backend vulnerability in the web admin dashboards of one of India’s largest pharmacy chains led to the exposure of thousands of online orders, underscoring the growing cybersecurity challenges in healthcare and retail sectors.
Converge Bio, an AI-powered drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with support from prominent executives at Meta, OpenAI, and Wiz.
Converge Bio, an AI-powered drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with additional investments from executives at Meta, OpenAI, and Wiz. This capital injection aims to accelerate the development of innovative therapies using artificial intelligence.